Pelvic Lymph Node Dissection News Today

Biochemical recurrence (BCR) of prostate cancer is a condition that occurs in men who have previously been cured of prostate cancer. In BCR, prostate-specific antigen (PSA) is elevated above normal.

Flotufolastat fluorine-18 (Posluma), a new PSMA-targeted PET radiopharmaceutical, has been approved in the US for use in prostate cancer.

Investigators say bladder-preserving treatment should be offered to all patients, not just poor surgical candidates.

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).

Biochemical Recurrence of Prostate Cancer About The prostate is a walnut-sized gland that is a part of the male reproductive system. It secretes a fluid that nourishes and protects the sperms, which are the male reproductive cells. Cancer of the prostate is a major cause of concern in aging men. Prostate cancer usually resolves after primary therapy in the majority of men. However, in some men, a condition called biochemical recurrence (BCR) occurs, also known as biochemical relapse or PSA...